Drug LaunchThe FDA approved Sotatercept under brand name Winrevair for the treatment of PAH, with analysts increasing peak sales projections to approximately $11 billion, well above the sell side consensus.
Financial PerformanceMerck & Co., Inc. reported revenue of $15.8B, surpassing the consensus of $15.2B, and Non-GAAP EPS of $2.07 versus consensus of $1.99, showing strong financial performance.
Product PipelineThe upcoming product approvals and launches, including three PDUFAs in June, signal potential for future revenue streams.